LAHIVE & COCKFIELD LLP

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
lc@lahive.com

March 1, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: U.S. Patent Application No.: 10/731,463
For: *Amidine Derivatives for Treating Amyloidosis*
Inventors: Chalifour, Robert J. *et al.*
Filed: December 5, 2003
Our Ref. No.: NBI-105CN

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement (2 pages, in duplicate);
2. PTO Form 1449 (6 pages);
3. Copies of references cited in said PTO Form 1449 (180 references);
4. A copy of the International Preliminary Examination Report from PCT/CA02/01353 (9 pages); and
5. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in a package addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

March 1, 2004
Date

Theodore R. West, Reg. No. 47,202

Respectfully submitted,
LAHIVE & COCKFIELD, LLP

Theodore R. West
Registration No. 47,202
Agent for Applicants

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Chalifour, Robert J. *et al.*	Group Art Unit: 1621
Serial No.: 10/731,463	Examiner: Not Yet Assigned
Filed: December 5, 2003	
For: *AMIDINE DERIVATIVES FOR TREATING AMYLOIDOSIS*	
Attorney Docket No.: NBI-105CN	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in a package addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

March 1, 2004
Date of Signature and of Mail Deposit

By: _____
Theodore R. West
Registration No. 47,202
Agent for Applicants

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their representatives are aware of the following publications and information, listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. Reference ID Nos. A28, C14, C17, D9, D21, E13, E14, E1, E20, F4, F7, F17, and F18 were cited in an International Preliminary Examination Report during the prosecution of PCT/CA02/01353 dated September 12, 2003, which relates to the above-referenced application. A copy of the report and each cited publication is enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080..

Respectfully submitted,
LAHIVE & COCKFIELD, LLP

Theodore R. West
Registration No. 47,202
Agent for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400

Date: March 01, 2004

GAD/EAH/TRW/DLH/ipc
Enclosures

APPLICANT FACSIMILE OF FORM PTO-1449 REV. 8	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO	SERIAL NO.
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		NBI-105CN	10/731,463
		APPLICANT: Chalifour, *et al.*	
		FILING DATE: December 5, 2003	GROUP: 1621

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,324,794	Apr-82	Tidwell *et al.*	514	387	
	A2	4,397,863	Aug-83	Tidwell *et al.*	514	415	
	A3	4,515,625	May-85	Burow, Jr.	71	92	
	A4	4,522,811	Jun-85	Eppstein, *et al.*	514	2	
	A5	4,619,942	Oct-86	Tidwell, *et al.*	514	415	
	A6	4,933,347	Jun-90	Tidwell, *et al.*	514	256	
	A7	4,940,723	Jul-90	Tidwell, *et al.*	514	396	
	A8	4,963,589	Oct-90	Tidwell, *et al.*	514	636	
	A9	5,202,320	Apr-93	Tidwell, *et al.*	514	218	
	A10	5,206,236	Apr-93	Tidwell, *et al.*	514	218	
	A11	5,246,965	Sep-93	Main	514	532	
	A12	5,374,548	Dec-94	Caras	424	450	
	A13	5,387,742	Feb-95	Cordell	800	12	
	A14	5,399,311	Mar-95	Kasai, *et al.*	419	28	
	A15	5,428,051	Jun-95	Tidwell, *et al.*	514	394	
	A16	5,441,870	Aug-95	Seubert, *et al.*	435	7.1	
	A17	5,451,700	Sep-95	Morrissey *et al.*	564	165	
	A18	5,521,189	May-96	Boykin *et al.*	514	256	
	A19	5,538,845	Jul-96	Knops, *et al.*	435	6	
	A20	5,547,841	Aug-96	Marotta, *et al.*	435	6	
	A21	5,552,426	Sep-96	Lunn, *et al.*	514	394	
	A22	5,574,059	Nov-96	Regunathan *et al.*	514	397	
	A23	5,578,631	Nov-96	Tidwell, *et al.*	514	394	
	A24	5,594,138	Jan-97	Dykstra, *et al.*	540	596	
	A25	5,602,172	Feb-97	Boykin, *et al.*	514	461	
	A26	5,605,811	Feb-97	Seubert , *et al.*	435	29	
	A27	5,606,058	Feb-97	Boykin, *et al.*	544	242	
	A28	5,612,363	Mar-97	Mohan, *et al.*	514	392	
	A29	5,622,955	Apr-97	Boykin, *et al.*	514	256	
	A30	5,627,184	May-97	Boykin *et al.*	514	256	
	A31	5,639,755	Jun-97	Dykstra, *et al.*	514	256	
	A32	5,643,562	Jul-97	Kisilevsky, *et al.*	424	78.31	
	A33	5,643,935	Jul-97	Dykstra, *et al.*	514	394	
	A34	5,667,975	Sep-97	Dykstra, *et al.*	435	6	
	A35	5,668,166	Sep-97	Tidwell, *et al.*	514	411	
	A36	5,668,167	Sep-97	Tidwell, *et al.*	514	411	
	A37	5,686,456	Nov-97	Boykin, *et al.*	514	256	
	A38	5,686,477	Nov-97	Jarry *et al.*	514	377	
	A39	5,686,496	Nov-97	Anderskewitz *et al.*	514	637	

Examiner	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO	SERIAL NO.
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		NBI-105CN	10/731,463
		APPLICANT: Chalifour, *et al.*	
		FILING DATE: December 5, 2003	GROUP: 1621

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B1	5,720,936	Feb-98	Wadsworth, *et al.*	424	9.1	
	B2	5,721,106	Feb-98	Maggio, *et al.*	435	7.8	
	B3	5,723,288	Mar-98	Dykstra *et al.*	435	6	
	B4	5,723,495	Mar-98	Hall, *et al.*	514	633	
	B5	5,726,197	Mar-98	Clark *et al.*	514	387	
	B6	5,728,375	Mar-98	Kisilevsky, *et al.*	424	78.31	
	B7	5,731,332	Mar-98	Anderskewitz *et al.*	514	354	
	B8	5,792,782	Aug-98	Dykstra, *et al.*	514	394	
	B9	5,811,633	Sep-98	Wadsworth *et al.*	800	12	
	B10	5,817,686	Oct-98	Dykstra, *et al.*	514	394	
	B11	5,817,687	Oct-98	Dykstra, *et al.*	514	394	
	B12	5,840,294	Nov-98	Kisilevsky, *et al.*	424	78.31	
	B13	5,843,980	Dec-98	Hall, *et al.*	514	438	
	B14	5,871,924	Feb-99	Yarus, *et al.*	435	6	
	B15	5,935,982	Aug-99	Dykstra, *et al.*	514	394	
	B16	5,939,440	Aug-99	Dykstra, *et al.*	514	338	
	B17	5,972,328	Oct-99	Kisilevsky, *et al.*	424	78.31	
	B18	5,972,969	Oct-99	Dykstra, *et al.*	514	338	
	B19	6,008,247	Dec-99	Boykin, *et al.*	514	471	
	B20	6,017,941	Jan-00	Dykstra, *et al.*	514	394	
	B21	6,025,398	Feb-00	Hall, *et al.*	514	633	
	B22	6,037,377	Mar-00	Anderskewitz *et al.*	514	635	
	B23	6,046,226	Apr-00	Dykstra, *et al.*	514	394	
	B24	6,127,423	Oct-00	Anderskewitz *et al.*	514	637	
	B25	6,127,554	Oct-00	Boykin, *et al.*	549	504	
	B26	6,133,281	Oct-00	Gonzalez-Cadavid *et al.*	514	289	
	B27	6,156,779	Dec-00	Dykstra, *et al.*	514	397	
	B28	2003/0130303	Jul-03	Coe, *et al.*	514	300	
	B29	6,172,104 B1	Jan-03	Tidwell, *et al.*	514	443	
	B30	6,197,824 B1	Mar-03	Schromm *et al.*	514	637	
	B31	6,214,883 B1	Apr-03	Hall, *et al.*	514	633	
	B32	6,294,565 B1	Sep-03	Dykstra, *et al.*	514	397	
	B33	6,319,944 B1	Nov-03	Claiborne, *et al.*	514	452	
	B34	6,326,395 B1	Dec-03	Tidwell, *et al.*	514	461	
	B35	6,489,365 B1	Dec-03	Anderskewitz *et al.*	514	637	
	B36	6,625,612 B1	Sep-03	Tal *et al.*	707	102	
	B37	6,627,647 B1	Sep-03	Betageri	514	333	

Examiner	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO NBI-105CN	SERIAL NO. 10/731,463
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Chalifour, *et al.*	
		FILING DATE December 5, 2003	GROUP 1621

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	C1	6,635,668 B1	Oct-03	Tidwell *et al.*	514	394	
	C2	US 20010044468 A1	Nov-03	Hall *et al.*	514	574	
	C3	US 20030083362 A1	May-03	Boykin *et al.*	514	408	
	C4	US 20030199521 A1	Oct-03	Dykstra *et al.*	514	256	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
✓	C5	JP 72-79092	Aug-72	Japan			Abstract	
✓	C6	EP 0 518 818 A2	Dec-92	EPO				
✓	C7	WO 93/16036 A1	Aug-93	WO				
✓	C8	WO 94/11341 A1	May-94	WO				
✓	C9	EP 0 601 977 A1	Jun-94	EPO				
✓	C10	EP 941991 B1	May-01	EPO				
✓	C11	WO 95/19772 A1	Jul-95	WO				
✓	C12	WO 96/15126 A1	May-96	WO				
✓	C13	WO 96/28187	Sep-96	WO				
✓	C14	WO 98/13037 A1	Apr-98	WO				
✓	C15	WO 98/40381 A1	Sep-98	WO				
✓	C16	WO 98/55454 A2	Dec-98	WO				
✓	C17	WO 00/04893 A2, A3	Feb-00	WO				
✓	C18	WO 01/03680	Jan-01	WO				
✓	C19	WO 01/03685 A2	Jan-01	WO				
✓	C20	WO 01/32159 A2	May-01	WO				
✓	C21	WO 01/46175 A1	Jun-01	WO				
✓	C22	WO 01/85093	Nov-01	WO				
✓	C23	WO 02/02516 A2	Jan-02	WO				
✓	C24	WO 02/34715 A1	May-02	WO				
✓	C25	WO 02/36588 A2	May-02	WO				
✓	C26	WO 02/55025 A2	Jul-02	WO				
✓	C27	WO 02/058684	Aug-02	WO				
✓	C28	WO 02/058697	Aug-02	WO				
✓	C29	WO 02/062785 A1	Aug-02	WO				
✓	C30	WO 03/103598 A2	Dec-03	WO				
✓	C31	WO 03/017994 A1	Mar-03	WO				

Examiner	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO	SERIAL NO.
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		NBI-105CN	10/731,463
		APPLICANT: Chalifour, *et al.*	
		FILING DATE: December 5, 2003	GROUP: 1621

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

	D1	✓	Askanas V, *et al.*, "New advances in the understanding of sporadic inclusion-body myositis and hereditary inclusion-body myopathies." Curr. Opin. Rheumatol. 7(6), 486-96 (1995 Nov).
	D2	✓	Askanas V, *et al.*, "Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle." Proc. Nat'l Acad. Sci. U.S.A. 93(3), 1314-19 (1996 Feb).
	D3	✓	Bailly, C, *et al.*, Sequence-selective binding to DNA of bis(amidinophenoxy)alkanes related to propamidine and pentamidine. Biochem J. 1997 Apr 1;323 (Pt 1):23-31
	D4	✓	Baldwin, *et al.*, "Research Advances," in Alzheimer's Disease and Related Disorders, John Wiley and Sons, New York , 757-773(1995).
	D5	✓	Bayer, TA, *et al.*, "Key factors in Alzheimer's disease: β amyloid precursor protein processing, metabolism and intraneuronal transport," Brain Pathology 11, 111 (2001).
	D6	✓	Beekes, M, *et al.*, "Western blot mapping of disease-specific amyloid in various animal species and humans with transmissible spongiform encephalopathies using a high-yield purification method." J. Gen. Virol. 76(Pt 10), 2567-76 (1995 Oct).
	D7	✓	Benson, DA, *et al.*, Nucl. Acids Res. 28(1):15-18 (2000)
	D8	✓	Berge, *et al.*, "Pharmaceutical salts." J. Pharm. Sci. 66(1), 1-19 (1977 Jan).
	D9	✓	Bilik P., *et al.*, "Novel dications with unfused aromatic systems: trithiophene and trifuran derivatives of furimidazoline," CHEMBIOCHEM 2(78), 559-69 (2001).
	D10	✓	Boado, R.J., *et al.*, Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. J. Pharm. Sci. 87(11), 1308-15 (1998 Nov).
	D11	✓	Bohrmann, B., *et al.*, Self-assembly of β-amyloid 42 is retarded by small molecular ligands at the stage of structural intermediates. J. Struct. Biol. 130(2-3), 232-46 (2000 Jun).
	D12	✓	Boykin, D. W *et al.*, Anti-Pneumocystis carinii pneumonia activity of dicationic diaryl methylpyrimidines. European Journal of Medicinal Chemistry (1997), 32(12), 965-972.
	D13	✓	Cardin, A.D, *et al.*, Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis. 9(1), 21-32 (1989 Jan-Feb).
	D14	✓	Caughey, GH, *et al.*, Bis(5-amidino-2-benzimidazolyl)methane and related amidines are potent, reversible inhibitors of mast cell tryptases. J Pharmacol Exp Ther. 1993 Feb;264(2):676-82.
	D15	✓	Chauhan, PM, *et al.*, Effect of new diamidines against Leishmania donovani infection. Indian J Exp Biol. 1993 Feb;31(2):196-8
	D16	✓	Chongprasert, S., *et al.*, Effects of freeze-dry processing conditions on the crystallization of pentamidine isethionate. J. Pharm. Sci. 87(9), 1155-60 (1998 Sep).
	D17	✓	Clercq ED, Dann O., Diaryl amidine derivatives as oncornaviral DNA polymerase inhibitors. J Med Chem. 1980 Jul;23(7):787-95
	D18	✓	Contreras, J.M., *et al.*, "Aminopyridazines as acetylcholinesterase inhibitors." J. Med. Chem. 42(4), 730-41 (1999 Feb).
	D19	✓	Czarny A, *et al.*, Analysis of van der Waals and Electrostatic Contributions in the Interactions of Minor Groove Binding Benzimidazoles with DNA J. Am. Chem. Soc.; 1995; 117(16); 4716-4717
	D20	✓	de Koning, EJ, *et al.*, "Diabetes mellitus in Macaca mulatta monkeys is characterised by islet amyloidosis and reduction in beta-cell population." Diabetologia 36(5), 378-84 (1993 May).
	D21	✓	Donkor, IO, *et al.*, "Pentamidine congeners: 2,2-butenebridged aromatic diamidines and diimidazolines as potential anti-Pneumocystis carinii pneumonia agents," J. Med. Chem. 37(26), 4554-57 (1994).
	D22	✓	Dubovi, EJ, *et al.*, Inhibition of respiratory syncytial virus-host cell interactions by mono- and diamidines. Antimicrob Agents Chemother. 1981 Apr;19(4):649-56
	D23	✓	Dunbar PG, *et al.*, Design, synthesis, and neurochemical evaluation of 2-amino-5-(alkoxycarbonyl)-3,4,5,6-tetrahydropyridines and 2-amino-5-(alkoxycarbonyl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1994 Aug 19;37(17):2774-82
	D24	✓	Fairley, TA, *et al.*, Structure, DNA minor groove binding, and base pair specificity of alkyl- and aryl-linked bis(amidinobenzimidazoles) and bis(amidinoindoles). J Med Chem. 1993 Jun 11;36(12):1746-53
	D25	✓	Frangione, B, *et al.*, "Familial cerebral amyloid angiopathy related to stroke and dementia." Amyloid. 8(Suppl 1), 36-42, Review (2001 Jul).
	D26	✓	Garcia-Sevilla J, *et al.*, I2-imidazoline receptors in the healthy and pathologic human brain. Ann N Y Acad Sci. 1995 Jul 12;763:178-93

Examiner	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO	SERIAL NO.
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		NBI-105CN	10/731,463
		APPLICANT: Chalifour, *et al.*	
		FILING DATE: December 5, 2003	GROUP: 1621

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

	E1	✓	Garcia-Sevilla JA, "Imidazoline receptor proteins in brains of patients with Alzheimer's disease." Neurosci. Lett. 247(2-3), 95-98 (1998 May).
	E2	✓	Geratz, JD, *et al.*, Amidino-substituted aromatic heterocycles as probes of the specificity pocket of trypsin-like proteases. Arch Biochem Biophys. 1979 Oct 15;197(2):551-9.
	E3	✓	Geratz, JD, *et al.*, Novel bis(benzamidino) compounds with an aromatic central link. Inhibitors of thrombin, pancreatic kallikrein, trypsin, and complement. J Med Chem. 1976 May;19(5):634-9
	E4	✓	Geratz, JD, *et al.*, Inhibitory effect of amidino-substituted heterocyclic compounds on the amidase activity of plasmin and of high and low molecular weight urokinase and on urokinase-induced plasminogen activation. Thromb Res. 1981 Oct 1-15;24(1-2):73-83
	E5	✓	Gervais, F, "Amyloid – Those Deadly Fibrils." Eur. Biopham. Review, 40-42 (Autumn 2001)
	E6	✓	Giamarellou, H, *et al.*, 'Methicillin resistant' Staphylococcus aureus infections during 1978- 79: clinical and bacteriologic observations J. Antimicrob. Chemother. 1981 7: 649-655
	E7	✓	Glenner, GG, *et al.*, "Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein." Biochem. Biophys. Res. Commun. 122(3), 1131-35 (1984 Aug).
	E8	✓	Glenner, GG, *et al.*, "Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein." Biochem. Biophys. Res. Commun. 120(3), 885-90 (1984 May).
	E9	✓	Golde, TE, "Alzheimer disease therapy: Can the amyloid cascade be halted?" J. Clin. Invest. 111, 11-18 (2003).
	E10	✓	Gouras, GK, "Current theories for the molecular and cellular pathogenesis of Alzheimer's disease," Exp. Rev. Mol. Med. (31 May 2001), http://www-ermm.cbcu.cam.ac.uk/01003167h.htm.
	E11	✓	Hall, JE, *et al.*, Anti-Pneumocystis activities of aromatic diamidoxime prodrugs. Antimicrob Agents Chemother. 1998 Mar;42(3):666-74
	E12	✓	Hardy J, Selkoe DJ., "The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics." Science 297(5580), 353-56 (2002 Jul).
	E13	✓	Huang, T.L. , *et al.*, "Synthesis and anti-Pneumocystis carinii activity of piperidine-linked aromatic diimidazolines," Bioorg. Med. Chem. Lett. 6(17), 2087-90 (1996).
	E14	✓	Jones SK, *et al.*, "Novel pentamidine analogs in the treatment of experimental Pneumocystis carinii pneumonia." Antimicrob. Agents Chemother. 34(6), 1026-30 (1990 Jun).
	E15	✓	Lambert MP, *et al.*, "Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins." Proc. Nat'l Acad. Sci. U.S.A. 95(11), 6448-53 (1998 May).
	E16	✓	Lansiaux, A *et al.*, Distribution of furamidine analogues in tumor cells: influence of the number of positive charges. J Med Chem. 2002 May 9;45(10):1994-2002
	E17	✓	Lorenzo A, *et al.*, "Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368(6473), 756-60 (1994 Apr).
	E18	✓	Mayeux, R, *et al.*, "Drug Therapy. Treatment of Alzheimer's Disease," New Engl. J. Med. 341(22), 1670-79 (1999).
	E19	✓	Messer WS Jr, *et al.*, Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists. J Med Chem. 1997 Apr 11;40(8):1230-46
	E20	✓	Nandi G., *et al.*, "Synthesis, spectroscopic properties and antileishmanial screening of some pentamidine analogs," J. Indian Chem. Soc. 70(6), 527-31 (1993).
	E21	✓	Opie EL, "On the relation of chronic interstitial pancreatitis to the islands of Langerhans and to diabetes mellitus." J. Exp. Med. 5, 397-428 (1900-01).
	E22	✓	Parrish RF,*et al.*, Structure-activity relationships for the inhibition of acrosin by benzamidine derivatives. J Med Chem. 1978 Nov;21(11):1132-6
	E23	✓	Ren, J, *et al.*, Molecular recognition of a RNA:DNA hybrid structure. J Am Chem Soc. 2001 Jul 11;123(27):6742-3
	E24	✓	Reynolds IJ, *et al.*, Pentamidine is an N-methyl-D-aspartate receptor antagonist and is neuroprotective in vitro. J Neurosci. 1992 Mar;12(3):970-5.
	E25	✓	Reynolds IJ, *et al.*, Studies on the effects of several pentamidine analogues on the NMDA receptor. Eur J Pharmacol. 1993 Jan 15;244(2):175-9
	E26	✓	Rupniak, N.M., *et al.*, "Reversal of cognitive impairment by heptyl physostigmine, a long-lasting cholinesterase inhibitor, in primates." J. Neurol. Sci. 107(2), 246-49 (1992 Feb).

Examiner	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO	SERIAL NO.
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		NBI-105CN	10/731,463
		APPLICANT: Chalifour, *et al.*	
		FILING DATE: December 5, 2003	GROUP: 1621

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

	F1	✓	Schauhan, P. M., Antiparasitic agents. Part VI. Synthesis of 1,2-, 1,3-, and 1,4-bis[4-substituted (aryloxy)]benzenes and their biological activities Organic Chemistry Including Medicinal Chemistry (1988), 27B(1), 38-42
	F2	✓	Selkoe, DJ, "Alzheimer's Disease: Genes, Proteins, and Therapy," Physiol. Rev. 81(2), 741-66 (April 2001).
	F3	✓	Silverman, RB, " The Organic Chemistry of Drug Design and Drug Action," Academic Press, Chapter 8 (1992).
	F4	✓	Soto J, *et al.*, "Dissociation between I2-imidazoline receptors and MAO-B activity in platelets of patients with Alzheimer's type dementia." J. Psychiatr. Res. 33(3), 251-27 (1999 May-Jun).
	F5	✓	Steck, EA, *et al.*, Leishmania donovani, Plasmodium berghei, Trypanosoma rhodesiense: antiprotozoal effects of some amidine types. Exp Parasitol. 1981 Dec;52(3):404-13
	F6	✓	Tidwell, RR, et al Strategies for anticoagulation with synthetic protease inhibitors. Xa inhibitors versus thrombin inhibitors. Thromb Res. 1980 Aug 1;19(3):339-49.
	F7	✓	Tao Bin, *et al.*, "Novel bisbenzamidines and bisbenzimidazolines as noncompetitive NMDA receptor antagonists," Bioorg. Med. Chem. Lett. 9(9), 1299-1304 (1999).
	F8	✓	Tidwell, RR, et al Analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine) in the treatment of experimental Pneumocystis carinii pneumonia. J Med Chem. 1990 Apr;33(4):1252-7
	F9	✓	Tidwell, RR, *et al.* Aromatic amidines: comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin, and trypsin. J Med Chem. 1983 Feb;26(2):294-8
	F10	✓	Tidwell, RR, *et al.* Diarylamidine derivatives with one or both of the aryl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esteroproteases. J Med Chem. 1978 Jul;21(7):613-23
	F11	✓	Verner, E, *et al.*, Development of serine protease inhibitors displaying a multicentered short (<2.3 .ANG.) hydrogen bond binding mode: Inhibitors of urokinase-type plasminogen activator and factor Xa. Journal of Medicinal Chemistry (2001), 44(17), 2753-2771
	F12	✓	Wang, L *et al.*, Evaluation of the influence of compound structure on stacked-dimer formation in the DNA minor groove. Biochemistry. 2001 Feb 27;40(8):2511-21
	F13	✓	Weidner-Wells, M. A., *et al.* Amidino benzimidazole inhibitors of bacterial two-component systems. Bioorganic & Medicinal Chemistry Letters (2001), 11(12), 1545-1548
	F14	✓	Westermark, P., *et al.*, "The pancreatic islet cells in insular amyloidosis in human diabetic and non-diabetic adults." Acta Pathol. Microbiol. Scand. [A] 81(3), 291-300 (1973 May).
	F15	✓	Wilson, WD, *et al.*, The search for structure-specific nucleic acid-interactive drugs: effects of compound structure on RNA versus DNA interaction strength. Biochemistry. 1993 Apr 20;32(15):4098-104
	F16	✓	Wood, DH, *et al.*, "Pentamidine is a potent inhibitor of (3H)Dazoxan binding to Imidazoline I2 receptors", Yeast, Chichester, Sussex, GB, vol. 881, 21 June 1999, pages 110-113.
	F17	✓	Wood, DH, *et al.*, "1,5-Bis(4-amidinophenoxy)pentane (pentamidine) is a potent inhibitor of [3H]idazoxan binding to imidazoline I2 binding sites." Eur. J. Pharmacol. 353(1), 97-103 (1998 Jul).
	F18	✓	Wood, DH, *et al.*, "Pentamidine is a potent inhibitor of [3H]idazoxan binding to imidazoline I2 receptors." Ann. N.Y. Acad. Sci. 881, 110-13 (1999 Jun).
	F19	✓	Zhang, *et al.*, "Biochemical characterization of the gamma-secretase activity that produces beta-amyloid peptides." Biochemistry 40(16), 5049-55 (2001 Apr).
	F20	✓	Zhang, *et al.*, "Enantioselective synthesis of oxiranes by the reactions of dimethylsulfonium methylide and aromatic aldehydes and ketones in the presence of chiral micelles." Tetrahedron: Asymmetry 8(16), 2723-25 (1997).
	F21	✓	Zhang, *et al.*, "Calpain inhibitor I increases beta-amyloid peptide production by inhibiting the degradation of the substrate of gamma-secretase. Evidence that substrate availability limits beta-amyloid peptide production." J Biol Chem. 274(13):8966-72 1999 Mar

Examiner	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.